Intracoital subfoveal hemorrhage after tadalafil (cialis) premedication: A case report

Tommaso Rossi, Barbara Boccassini, Luca Placentino, Mario Iossa, Maria Giulia Mutolo, Ciro Tamburrelli

Research output: Contribution to journalArticle

Abstract

Purpose: The purpose of this study is to report the first case, to our knowledge, of intracoital subfoveal hemorrhage occurring 1 hour after tadalafil premedication in a patient with previously undiagnosed retinal angiomatous proliferation and erectile dysfunction. Methods: This is an interventional case report. The patient underwent Snellen vision acuity measurement, anterior and posterior segment biomicroscopy, and indirect ophthalmoscopy. Optical coherence tomography, fluorescein angiography, and indocyanine green angiography were also performed as needed. Recombinant tissue plasminogen activator 100 μg/0.1 mL and 0.3 mL pure SF6 gas were injected in the vitreous on presentation. Four days later, the patient received 1.25 mg/0.1 mL of intravitreal bevacizumab. Results: One day after recombinant tissue plasminogen activator and gas injection, visual acuity rose to 20/60-2. A week later, visual acuity was unchanged, and the subretinal hemorrhage displaced from the foveola. Optical coherence tomography showed a marked regression of submacular thickening. Conclusion: Despite strict time correlation, the submacular hemorrhage cannot be unequivocally attributed to tadalafil assumption because many other risk factors are to be considered: the Valsalva maneuver above all. Nonetheless, a suspicion should be raised, at least as a cofactor, given the drug mechanism of action and the report of vascular abnormalities bleeding in the literature, including cerebral arterovenous malformation and epistaxis. Caution should be exercised in the prescription of phosphodiesterase type 5 inhibitors to patients with known vascular abnormalities including retinal and choroidal abnormalities: retinal angiomatous proliferation, classic and occult neovascularization of any origin, and also, possibly, hemangioma.

Original languageEnglish
Pages (from-to)377-380
Number of pages4
JournalRetinal Cases and Brief Reports
Volume4
Issue number4
DOIs
Publication statusPublished - Sep 2010

Fingerprint

Premedication
Hemorrhage
Optical Coherence Tomography
Tissue Plasminogen Activator
Visual Acuity
Blood Vessels
Gases
Valsalva Maneuver
Phosphodiesterase 5 Inhibitors
Ophthalmoscopy
Epistaxis
Indocyanine Green
Fluorescein Angiography
Erectile Dysfunction
Hemangioma
Prescriptions
Angiography
Injections
Tadalafil
Pharmaceutical Preparations

Keywords

  • Choroidal neovascularization
  • Phosphodiesterase type 5 inhibitors
  • Retinal angiomatous proliferation
  • Subfoveal hemorrhage
  • Subretinal bleeding
  • Tadalafil.

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Rossi, T., Boccassini, B., Placentino, L., Iossa, M., Mutolo, M. G., & Tamburrelli, C. (2010). Intracoital subfoveal hemorrhage after tadalafil (cialis) premedication: A case report. Retinal Cases and Brief Reports, 4(4), 377-380. https://doi.org/10.1097/ICB.0b013e3181babef2

Intracoital subfoveal hemorrhage after tadalafil (cialis) premedication : A case report. / Rossi, Tommaso; Boccassini, Barbara; Placentino, Luca; Iossa, Mario; Mutolo, Maria Giulia; Tamburrelli, Ciro.

In: Retinal Cases and Brief Reports, Vol. 4, No. 4, 09.2010, p. 377-380.

Research output: Contribution to journalArticle

Rossi, T, Boccassini, B, Placentino, L, Iossa, M, Mutolo, MG & Tamburrelli, C 2010, 'Intracoital subfoveal hemorrhage after tadalafil (cialis) premedication: A case report', Retinal Cases and Brief Reports, vol. 4, no. 4, pp. 377-380. https://doi.org/10.1097/ICB.0b013e3181babef2
Rossi, Tommaso ; Boccassini, Barbara ; Placentino, Luca ; Iossa, Mario ; Mutolo, Maria Giulia ; Tamburrelli, Ciro. / Intracoital subfoveal hemorrhage after tadalafil (cialis) premedication : A case report. In: Retinal Cases and Brief Reports. 2010 ; Vol. 4, No. 4. pp. 377-380.
@article{a1201967b97d4f678047b267ab3427a6,
title = "Intracoital subfoveal hemorrhage after tadalafil (cialis) premedication: A case report",
abstract = "Purpose: The purpose of this study is to report the first case, to our knowledge, of intracoital subfoveal hemorrhage occurring 1 hour after tadalafil premedication in a patient with previously undiagnosed retinal angiomatous proliferation and erectile dysfunction. Methods: This is an interventional case report. The patient underwent Snellen vision acuity measurement, anterior and posterior segment biomicroscopy, and indirect ophthalmoscopy. Optical coherence tomography, fluorescein angiography, and indocyanine green angiography were also performed as needed. Recombinant tissue plasminogen activator 100 μg/0.1 mL and 0.3 mL pure SF6 gas were injected in the vitreous on presentation. Four days later, the patient received 1.25 mg/0.1 mL of intravitreal bevacizumab. Results: One day after recombinant tissue plasminogen activator and gas injection, visual acuity rose to 20/60-2. A week later, visual acuity was unchanged, and the subretinal hemorrhage displaced from the foveola. Optical coherence tomography showed a marked regression of submacular thickening. Conclusion: Despite strict time correlation, the submacular hemorrhage cannot be unequivocally attributed to tadalafil assumption because many other risk factors are to be considered: the Valsalva maneuver above all. Nonetheless, a suspicion should be raised, at least as a cofactor, given the drug mechanism of action and the report of vascular abnormalities bleeding in the literature, including cerebral arterovenous malformation and epistaxis. Caution should be exercised in the prescription of phosphodiesterase type 5 inhibitors to patients with known vascular abnormalities including retinal and choroidal abnormalities: retinal angiomatous proliferation, classic and occult neovascularization of any origin, and also, possibly, hemangioma.",
keywords = "Choroidal neovascularization, Phosphodiesterase type 5 inhibitors, Retinal angiomatous proliferation, Subfoveal hemorrhage, Subretinal bleeding, Tadalafil.",
author = "Tommaso Rossi and Barbara Boccassini and Luca Placentino and Mario Iossa and Mutolo, {Maria Giulia} and Ciro Tamburrelli",
year = "2010",
month = "9",
doi = "10.1097/ICB.0b013e3181babef2",
language = "English",
volume = "4",
pages = "377--380",
journal = "Retinal Cases and Brief Reports",
issn = "1935-1089",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Intracoital subfoveal hemorrhage after tadalafil (cialis) premedication

T2 - A case report

AU - Rossi, Tommaso

AU - Boccassini, Barbara

AU - Placentino, Luca

AU - Iossa, Mario

AU - Mutolo, Maria Giulia

AU - Tamburrelli, Ciro

PY - 2010/9

Y1 - 2010/9

N2 - Purpose: The purpose of this study is to report the first case, to our knowledge, of intracoital subfoveal hemorrhage occurring 1 hour after tadalafil premedication in a patient with previously undiagnosed retinal angiomatous proliferation and erectile dysfunction. Methods: This is an interventional case report. The patient underwent Snellen vision acuity measurement, anterior and posterior segment biomicroscopy, and indirect ophthalmoscopy. Optical coherence tomography, fluorescein angiography, and indocyanine green angiography were also performed as needed. Recombinant tissue plasminogen activator 100 μg/0.1 mL and 0.3 mL pure SF6 gas were injected in the vitreous on presentation. Four days later, the patient received 1.25 mg/0.1 mL of intravitreal bevacizumab. Results: One day after recombinant tissue plasminogen activator and gas injection, visual acuity rose to 20/60-2. A week later, visual acuity was unchanged, and the subretinal hemorrhage displaced from the foveola. Optical coherence tomography showed a marked regression of submacular thickening. Conclusion: Despite strict time correlation, the submacular hemorrhage cannot be unequivocally attributed to tadalafil assumption because many other risk factors are to be considered: the Valsalva maneuver above all. Nonetheless, a suspicion should be raised, at least as a cofactor, given the drug mechanism of action and the report of vascular abnormalities bleeding in the literature, including cerebral arterovenous malformation and epistaxis. Caution should be exercised in the prescription of phosphodiesterase type 5 inhibitors to patients with known vascular abnormalities including retinal and choroidal abnormalities: retinal angiomatous proliferation, classic and occult neovascularization of any origin, and also, possibly, hemangioma.

AB - Purpose: The purpose of this study is to report the first case, to our knowledge, of intracoital subfoveal hemorrhage occurring 1 hour after tadalafil premedication in a patient with previously undiagnosed retinal angiomatous proliferation and erectile dysfunction. Methods: This is an interventional case report. The patient underwent Snellen vision acuity measurement, anterior and posterior segment biomicroscopy, and indirect ophthalmoscopy. Optical coherence tomography, fluorescein angiography, and indocyanine green angiography were also performed as needed. Recombinant tissue plasminogen activator 100 μg/0.1 mL and 0.3 mL pure SF6 gas were injected in the vitreous on presentation. Four days later, the patient received 1.25 mg/0.1 mL of intravitreal bevacizumab. Results: One day after recombinant tissue plasminogen activator and gas injection, visual acuity rose to 20/60-2. A week later, visual acuity was unchanged, and the subretinal hemorrhage displaced from the foveola. Optical coherence tomography showed a marked regression of submacular thickening. Conclusion: Despite strict time correlation, the submacular hemorrhage cannot be unequivocally attributed to tadalafil assumption because many other risk factors are to be considered: the Valsalva maneuver above all. Nonetheless, a suspicion should be raised, at least as a cofactor, given the drug mechanism of action and the report of vascular abnormalities bleeding in the literature, including cerebral arterovenous malformation and epistaxis. Caution should be exercised in the prescription of phosphodiesterase type 5 inhibitors to patients with known vascular abnormalities including retinal and choroidal abnormalities: retinal angiomatous proliferation, classic and occult neovascularization of any origin, and also, possibly, hemangioma.

KW - Choroidal neovascularization

KW - Phosphodiesterase type 5 inhibitors

KW - Retinal angiomatous proliferation

KW - Subfoveal hemorrhage

KW - Subretinal bleeding

KW - Tadalafil.

UR - http://www.scopus.com/inward/record.url?scp=80052227074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052227074&partnerID=8YFLogxK

U2 - 10.1097/ICB.0b013e3181babef2

DO - 10.1097/ICB.0b013e3181babef2

M3 - Article

AN - SCOPUS:80052227074

VL - 4

SP - 377

EP - 380

JO - Retinal Cases and Brief Reports

JF - Retinal Cases and Brief Reports

SN - 1935-1089

IS - 4

ER -